Registry of Lobbyists
Version 1 of 2 (1997-02-28 to 1998-02-27) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
NOVARTIS PHARMACEUTICALS CANADA INC / NOVARTIS PHARMA CANADA INC
385 BOUL BOUCHARD DORVAL, QC H9S 1A9 Canada |
| Telephone number: | 514-633-7876 |
| Fax number: | 514-631-0047 |
| Responsible officer name and position during the period of this registration: | JEAN-PAUL BEDARD, DIRECTEUR EXECUTIF, AFFAIRES EXTERNES |
| Description of activities: | RECHERCHE ET DEVELOPPEMENT, FABRICATION, ET MARKETING D'UNE VASTE GAMME DE PRODUITS PHARMACEUTIQUES DANS DIFFERENTES DOMAINES THERAPEUTIQUES. |
| The client is a subsidiary of the following parent companies: |
NOVARTIS
CH-4002 BASEL Switzerland |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Health Canada (HC), Industry Canada, Patented Medicine Prices Review Board (PMPRB) |
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format |
| Subject Matter: Areas of Concern: | Consumer Issues, Health, Industry, Intellectual Property, Science and Technology |
| Subject Matter: Particulars: | LOI C-91 REVISION DE LA LOI SUR LA PROTECTION DES MEDICAMENTS BREVETES.REVISION PARLEMENTAIRE DE LA LOI SUR LA PROTECTION DES MEDICAMENTS BREVETES (C-91)FORUM SANTE NATIONALEPUBLICITE DIRECTE AUX CONSOMMATEURSHEALTH PROTECTION BRANCH (HPB) TOUTES AUTRES QUESTIONS TOUCHANT LE DOMAINE PHARMACEUTIQUEPOLITIQUES DE SANTE NATIONALE |